By Fineline Cube 
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received approval from Peking University People’s Hospital to conduct two Phase III clinical studies (SHINING-2 and SHINING-3) for its Category 1 innovative polypeptide drug candidate RAY1225 in type 2 diabetes mellitus (T2DM). This marks a significant milestone in the development of this promising therapeutic option.
RAY1225 Drug Profile
RAY1225 is a long-acting glucagon-like peptide-1 (GLP-1) drug with dual activation activity of GLP-1 receptor and glucose-dependent insulin-promoting polypeptide (GIP) receptor. Previously, RAY1225 successfully achieved primary endpoints in Phase II trials conducted for T2DM and obese/overweight patients.
Clinical Study Objectives
SHINING-2 is designed to evaluate the safety and efficacy of RAY1225 when used as monotherapy in patients with T2DM. SHINING-3 will assess the efficacy and risk profile of RAY1225 when combined with oral hypoglycemic drugs. These studies aim to further establish the therapeutic potential of RAY1225 in managing T2DM.-Fineline Info & Tech